<DOC>
	<DOCNO>NCT00003589</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . It yet know combination chemotherapy regimen effective treat advanced non-small cell lung cancer . PURPOSE : Randomized phase III trial compare effectiveness three different combination chemotherapy regimens treat patient advance non-small cell lung cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Advanced Non-small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Compare overall survival paclitaxel/cisplatin ( arm I ) , gemcitabine/cisplatin ( arm II ) , paclitaxel/gemcitabine ( arm III ) patient advance non-small cell lung cancer . II . Determine response rate , duration response , progression-free survival , toxicity , quality life patient randomize three treatment arm . OUTLINE : This randomize , multicenter study . Patients stratify accord performance status ( 0-1 v 2 ) stage disease ( locally advance vs metastatic ) . Patients randomize receive paclitaxel IV 3 hour day 1 follow cisplatin IV day 1 every 3 week ( arm I ) , gemcitabine IV 30-60 minute day 1 8 cisplatin IV day 1 every 3 week ( arm II ) , paclitaxel IV 3 hour day 1 follow gemcitabine IV 30-60 minute day 1 8 every 3 week ( arm III ) . Patients receive least 2 course treatment . In absence unacceptable toxicity disease progression , patient may receive 6 course treatment . Quality life assess , , end treatment , every 6 week disease progression , every 3 month death . Patients follow every 6 week disease progression , every 3 month death . PROJECTED ACCRUAL : A total 450 patient ( 150 patient per arm ) accrue study 36 month .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm advanced nonsmall cell lung cancer progressive within 2 month prior study entry Stage IIIB due malignant pleural effusion supraclavicular lymph node involvement Stage IV At least 1 bidimensionally unidimensionally measurable target lesion Brain metastases leptomeningeal disease treat radiotherapy , stable without medication ( e.g. , steroid ) , asymptomatic allow PATIENT CHARACTERISTICS : Age : 18 75 Performance status : WHO 02 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 2,000/mm3 Platelet count least 100,000/mm3 Prothrombin time le 1.5 time normal Hepatic : Bilirubin great 1.25 time upper limit normal ( ULN ) ( great 2.5 time ULN due liver metastasis ) AST ALT le 3 time ULN ( great 5 time ULN due liver metastasis ) Renal : Creatinine clearance least 60 mL/min Cardiovascular : No uncontrolled cardiac disease , sign cardiac failure , rhythm disturbance require medication No myocardial infarction past 3 month Neurological : No preexist motor sensory neurotoxicity grade 2 great Other : No active uncontrolled infection Not poor medical risk due nonmalignant disease No secondary primary malignancy past 5 year ( exclude melanoma , breast cancer , hypernephroma ) except carcinoma situ cervix adequately treat basal cell carcinoma skin No psychological condition might hamper compliance study Not pregnant Effective contraception require fertile patient 3 month study PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since prior immunotherapy No concurrent colony stimulate factor except secondary prophylaxis case infection severe neutropenia No concurrent immunotherapy Chemotherapy : No prior chemotherapy advance disease , include intracavitary chemotherapy At least 1 year since prior neoadjuvant adjuvant chemotherapy No concurrent chemotherapy Endocrine therapy : See Disease Characteristics No concurrent hormonal agent ( except corticosteroid antiemetic prophylaxis ) Radiotherapy : Prior radiotherapy include target lesion evaluation At least 4 week since prior radiotherapy Concurrent palliative radiotherapy allow indicator lesion outside radiation field Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>recurrent small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
</DOC>